微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 48.38% | 6.4% | 1.54% | 72/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.65% | 1.21% | 6.07% | 84/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 44.92% | -0.54% | -0.28% | 89/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 45.05% | -6.2% | -0.93% | 90/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 45.47% | -3.1% | -3.42% | 85/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.08% | -16.78% | 4.24% | 86/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.17% | -18.99% | -5.96% | 94/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 48.03% | -16.24% | 2.35% | 86/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 46.93% | -23.85% | -17.05% | 86/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 56.57% | 37.1% | 1.47% | 70/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 55.75% | 44.78% | -2.77% | 68/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 57.34% | 61.81% | -6.95% | 68/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 61.62% | 96.39% | 49.34% | 53/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 41.26% | 41.83% | 7.15% | 98/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 38.51% | 37.99% | 8.67% | 99/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 35.44% | 19.36% | 12.94% | 112/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.38% | 2.62% | 7.85% | 104/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 29.09% | 3.62% | 4.25% | 130/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 27.91% | 5.04% | -5.99% | 110/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 29.69% | 4.47% | -2.9% | 116/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 30.58% | 12.28% | 8.9% | 97/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 28.08% | -2.11% | 5.68% | 123/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 26.57% | -1.52% | -6.5% | 99/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 28.42% | 3.84% | 4.35% | 104/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 27.23% | 3.61% | -5.06% | 97/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 28.68% | -5.01% | 6.32% | 121/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 26.98% | -10.69% | -1.42% | 94/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.37% | -10.12% | 4.13% | 99/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 26.28% | 2% | -12.96% | 94/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.2% | 2.93% | -0.03% | 106/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 30.21% | 2% | -0.8% | 78/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 30.45% | 2% | 3.79% | 81/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 29.34% | 1.17% | 1.17% | 91/159 | 48.44% | 退市金泰 | 95.93% | 行业排名> |
| 2015-12-31 | 29% | 4.66% | 4.66% | 82/159 | 46.24% | 贝达药业 | 95.58% | 行业排名> |